ALISA KNIFFEN: Open Payments
NPI 1811609555 · KEARNEY, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$781 in 28 payments from 8 companies in 2025. Trend: 2023 $83 · 2024 $84 · 2025 $781
Food & beverage: $781
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $350 |
| Otsuka America Pharmaceutical, Inc. | 5 | $199 |
| Alkermes, Inc. | 1 | $67 |
| Neurocrine BioSciences, Inc. | 1 | $65 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $29 |
| Janssen Pharmaceuticals, Inc | 1 | $23 |
| Lundbeck LLC | 1 | $19 |
Products named: VRAYLAR, ABILIFY ASIMTUFII, REXULTI, ARISTADA, INGREZZA, Qelbree, CAPLYTA, SPRAVATO.
Industry payments across NE — which companies pay providers there.
